Bbva Compass Bancshares Inc. Trims Position in Johnson & Johnson (NYSE:JNJ)

Bbva Compass Bancshares Inc. cut its stake in Johnson & Johnson (NYSE:JNJ) by 1.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 84,079 shares of the company’s stock after selling 1,585 shares during the quarter. Bbva Compass Bancshares Inc.’s holdings in Johnson & Johnson were worth $10,931,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in JNJ. BlackRock Inc. boosted its holdings in shares of Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after buying an additional 4,332,612 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after buying an additional 3,289,763 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after buying an additional 3,023,110 shares during the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Johnson & Johnson by 47.9% in the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after buying an additional 2,581,562 shares during the last quarter. Finally, Harbour Capital Advisors LLC boosted its holdings in shares of Johnson & Johnson by 13,327.8% in the second quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock worth $18,909,000 after buying an additional 2,482,843 shares during the last quarter. Hedge funds and other institutional investors own 65.70% of the company’s stock.

JNJ has been the topic of a number of research reports. Leerink Swann reissued an “outperform” rating and issued a $165.00 price objective (up previously from $150.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Royal Bank of Canada raised their price objective on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. BMO Capital Markets reissued a “positive” rating and issued a $152.00 price objective (up previously from $145.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and set a $155.00 price target (up previously from $149.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Hold” and an average price target of $146.16.

Shares of Johnson & Johnson (NYSE JNJ) traded up $3.17 during trading hours on Friday, reaching $129.53. 14,917,886 shares of the company’s stock traded hands, compared to its average volume of 9,100,000. The stock has a market capitalization of $347,980.00, a P/E ratio of 332.13, a P/E/G ratio of 2.33 and a beta of 0.74. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a twelve month low of $114.23 and a twelve month high of $148.32.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.02. The firm had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.58 earnings per share. research analysts expect that Johnson & Johnson will post 8.08 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.59%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s payout ratio is currently 861.54%.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2018/02/12/bbva-compass-bancshares-inc-has-10-93-million-stake-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply